Adoptive Immunotherapy for Cancer or Viruses

Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of immunology 2014-01, Vol.32 (1), p.189-225
Main Authors: Maus, Marcela V, Fraietta, Joseph A, Levine, Bruce L, Kalos, Michael, Zhao, Yangbing, June, Carl H
Format: Article
Language:English
Subjects:
adaptive immunity
adoptive immunotherapy
Adoptive Transfer
Animals
Antigens - genetics
Antigens - immunology
Biomarkers
Cell- and Tissue-Based Therapy
chimeric antigen receptor
gene transfer
Gene Transfer Techniques
Genetic Therapy
Humans
Immunotherapy, Adoptive
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - therapy
Receptors, Antigen, T-Cell - immunology
Receptors, Antigen, T-Cell - metabolism
T-Cell Antigen Receptor Specificity - immunology
T-Lymphocyte Subsets - cytology
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - metabolism
Transduction, Genetic
Virus Diseases - genetics
Virus Diseases - immunology
Virus Diseases - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target toxicity. Given recent advances in efficacy in numerous pilot trials, the next steps in clinical development will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.
ISSN:0732-0582
1545-3278
DOI:10.1146/annurev-immunol-032713-120136